Skip to main content

Table 2 Effect of HFD and AuNP treatment on metabolic parameters

From: Gold nanoparticles as cell regulators: beneficial effects of gold nanoparticles on the metabolic profile of mice with pre-existing obesity

 

Chow

OB

OB-EAu

OB-LAu

OB-HAu

Area under the curve (mM min)

1452 ± 42

2270 ± 210**

1812 ± 118*,††

1758 ± 99*,††

1945 ± 101**,†

Plasma insulin (ng/mL)

0.012 ± 0.001

0.032 ± 0.007*

0.039 ± 0.011*

0.028 ± 0.004

0.035 ± 0.007*

Plasma NEFA (mM)

2.07 ± 0.16

3.38 ± 0.31*

2.63 ± 0.21

2.56 ± 0.23†

2.83 ± 0.35*

Plasma triglyceride (mM)

0.62 ± 0.09

0.60 ± 0.10

0.37 ± 0.04

0.34 ± 0.05*

0.40 ± 0.06

Plasma HDL-C (mM)

1.42 ± 0.35

1.64 ± 0.22

3.40 ± 0.34**,††

2.79 ± 0.20**,††

3.00 ± 0.23**,††

Plasma AST (U/L)

7.45 ± 1.35

50.14 ± 9.41*

41.94 ± 2.87*

25.30 ± 5.17†

23.46 ± 2.70†

Plasma ALT (U/L)

6.40 ± 0.68

20.01 ± 3.18*

12.08 ± 2.90

23.85 ± 3.32*

25.35 ± 4.41*

Liver triglyceride (mM/mg tissue)

0.05 ± 0.01

0.60 ± 0.07*

0.55 ± 0.04*

0.58 ± 0.05*

0.44 ± 0.05*,†

  1. Results are expressed as mean ± S.E.M. Data were analysed by one-way ANOVA followed by post hoc Bonferroni test
  2. * P < 0.05, ** P < 0.01 vs Chow; † P < 0.05, †† P < 0.01 vs OB. n = 4–15